<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090400</url>
  </required_header>
  <id_info>
    <org_study_id>IP-2012-01</org_study_id>
    <secondary_id>2012-003131-28</secondary_id>
    <nct_id>NCT02090400</nct_id>
  </id_info>
  <brief_title>Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women</brief_title>
  <official_title>Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Palacios</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Palacios</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is see the changes in bone mineral density after discontinuation or&#xD;
      stop the use of bisphosphonates and make the switch to bazedoxifene).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary hypothesis is: &quot;Comparing to control group (Calcium+VitD), Bazedoxifene group&#xD;
      (20mg daily+ calcium+VitD) is efficient in reducing BMD in spine at 12 months of treatment.&#xD;
      in postmenopausal women switching from daily, weekly or monthly bisphosphonates therapy. It&#xD;
      is a non-inferiority study of Bazedoxifene compared to biphosphonates, being each patient its&#xD;
      own control from the baseline. It is a superiority study of Bazedoxifene compared to&#xD;
      Calcium+VitD.&#xD;
&#xD;
      Taking into account the difference in the percentage change observed in the total BMD of the&#xD;
      spine during 12 months in those patients treated with Bazedoxifene+Ca+VitD at least 110&#xD;
      patients should be included, 55 in each arm of treatment.&#xD;
&#xD;
      This simple size is going to allow us to detect the differences in the percentage change&#xD;
      observed in the total BMD of the spine during 12 months between the two treatment arms, being&#xD;
      the same or over 0.25%, with a significance level of 95%, an 80% power. It is estimated a&#xD;
      standard deviation of 0.5%, and a 10% lost follow-up rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lumbar Spine Bone Mineral Density (BMD)</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate the change in Lumbar Spine Bone Mineral Density (BMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers (BTM´s) carboxy-terminal collagen crosslinks (CTX) and 1 procollagen N-terminal (P1NP)</measure>
    <time_frame>6 and 12 months from baseline</time_frame>
    <description>To evaluate the effects of switching to Bazedoxifene 20mg in comparison with switching to calcium 500mg and 400 International Units (IU) vitamin D (OSTINE) daily on BTM's CTX and P1NP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMD at the femoral neck</measure>
    <time_frame>6 and 12 months from baseline</time_frame>
    <description>To evaluate the effects of switching to Bazedoxifene 20mg in comparison with switching to calcium 500mg and 400 IU vitamin D (OSTINE) daily on BMD at the femoral neck</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMD at total hip</measure>
    <time_frame>6 and 12 months from baseline</time_frame>
    <description>To evaluate the effects of switching to Bazedoxifene 20mg in comparison with switching to calcium 500mg and 400 IU vitamin D (OSTINE) daily on BMD at total hip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mammography</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>Changes in Mammography at12 months from baseline in the Breast Imaging Report and Database System (BI-RADS) classification</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subject reported treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM) and gastrointestinal symptoms using the Gastrointestinal Symptoms Rating Scale (GSRS)the Spanish versions</measure>
    <time_frame>At baseline, months 6 and 12</time_frame>
    <description>To evaluate the effects of switching to Bazedoxifene 20mg in comparison with switching to calcium 500mg and 400 IU vitamin D (OSTINE)daily on Subject reported treatment satisfaction using the Treatment Satisfaction Questionnaire for Medication (TSQM) and gastrointestinal symptoms using the Gastrointestinal Symptoms Rating Scale (GSRS)the Spanish versions</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bazedoxifene 20mg oral once a day and calcium 500mg and 400 IU vitamin D (OSTINE)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium/Vit D</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Calcium 500mg and 400 IU vitamin D (OSTINE )daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bazedoxifene</intervention_name>
    <description>20 mg Oral daily for 12 months</description>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <other_name>Conbriza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium/Vit D</intervention_name>
    <description>Calcium 500 mg / 400 IU Vit D</description>
    <arm_group_label>Bazedoxifene &amp; Calcium/Vit D</arm_group_label>
    <arm_group_label>Calcium/Vit D</arm_group_label>
    <other_name>Ostine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory postmenopausal women 55 years or older at screening&#xD;
&#xD;
          -  Have received daily, weekly or monthly oral bisphosphonates at least for 3 years and&#xD;
             treatment change is indicated (not responses to bisphosphonates, for bad tolerability&#xD;
             or for the potential risk of side effects in a long term treatment with&#xD;
             bisphosphonates-indicated by Federal Drug Administration, European Medicines Agency.&#xD;
&#xD;
          -  Subjects has stop bisphosphonates therapy no more than one month before screening&#xD;
             visit for subjects in daily or weekly bisphosphonates&#xD;
&#xD;
          -  Subjects has stop bisphosphonates therapy no more than two months before screening&#xD;
             visit for subjects in monthly bisphosphonates&#xD;
&#xD;
          -  Screening T-score at the lumbar spine ≤ -2.0 to -4.0 by Dual X ray Absorptiometry&#xD;
             (DXA) scan&#xD;
&#xD;
          -  At least 2 lumbar vertebrae must be evaluable by DXA&#xD;
&#xD;
          -  Al least one hip must be evaluable by DXA (for secondary objectives)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder that compromises the ability of the subject to give written informed&#xD;
             consent and/or to comply with study procedures&#xD;
&#xD;
          -  Current use of medication prescribed for osteoporosis other than oral bisphosphonates&#xD;
&#xD;
          -  Subjects who had received intravenous bisphosphonates or fluoride (except for dental&#xD;
             treatment)&#xD;
&#xD;
          -  Subjects who had received any Selective Estrogens Receptor Modulator (SERM), anabolic&#xD;
             steroids, systemic hormone replacement, calcitonin or calcitriol within 3 months.&#xD;
&#xD;
          -  Subjects who had received strontium ranelate, parathyroid hormone (PTH) or PTH&#xD;
             derivates within 1 year.&#xD;
&#xD;
          -  Hyper or hypothyroidism, current hyper or hypoparathyroidism&#xD;
&#xD;
          -  History of Venous Thromboembolism Event (VTE)&#xD;
&#xD;
          -  Significantly impaired renal function as determined by estimated Glomerular Filtration&#xD;
             Rate less 35 mL/min&#xD;
&#xD;
          -  Hyper or hypocalcemia&#xD;
&#xD;
          -  Vitamin D deficiency (serum 25 (OH) vit D level &lt; 20 ng/mL (&lt; 50nmol/L)&#xD;
&#xD;
          -  Any condition that could result in impaired calcium metabolism or metabolic bone&#xD;
             disease that could interfere with interpretation findings&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Santiago Palacios, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Gabinete Médico Velázquez</name>
      <address>
        <city>Madrid</city>
        <zip>28001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Palacios</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología EGR</name>
      <address>
        <city>Madrid</city>
        <zip>28023</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Women</keyword>
  <keyword>Osteoporosis, Postmenopausal</keyword>
  <keyword>Bazedoxifene</keyword>
  <keyword>BMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bazedoxifene</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

